Blinatumomab (Blincyto, Amgen) is indicated as 'monotherapy for the treatment of adults with Philadelphia-chromosome-negative CD19 positive B‑precursor acute lymphoblastic leukaemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%'.
Blinatumomab is administered by continuous intravenous infusion delivered at a constant rate using an infusion pump. A single cycle of blinatumomab treatment comprises continuous intravenous infusion at a dose of 28 micrograms/day for 28 days, followed by a 14‑day treatment-free interval.
The list price of blinatumomab is £2,017 per 38.5 microgram vial. The average cost of blinatumomab per cycle at the list price is £56,476 (company submission).
The company has a commercial arrangement. This makes blinatumomab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.